Antigen Testing May Be the Game Changer That Economies Need
Antigen tests are faster, cheaper and more scalable than the familiar molecular test for COVID-19. A new multibillion market could open up if the health care industry manages to establish a threshold for test accuracy. Broader acceptance of antigen tests should also bring significant revenue growth for the handful of public companies that have such products in the market today.
CFA, Research Analyst, Fundamental Growth and Core Equity
While health professionals know much more about COVID-19 today than at the beginning of 2020, containing the virus has proven to be difficult. Critical hurdles include: 1) asymptomatic people transmitting the virus and 2) the possibility of recovered patients getting reinfected. Add in the approaching winter season and it is clear that a second wave is clearly emerging as a risk to the economy. In this context, an accurate, fast and widely available detection test could keep economies open until a credible vaccine is developed.
The Three Primary COVID-19 Tests
There are three primary categories of COVID tests, each with varying costs, turnaround times and scalability. Molecular test is the most prevalent test for a current infection (the long nasal swab) and is the gold standard in terms of accuracy. The test also has a high throughput: large instruments can run hundreds of samples simultaneously though each cycle that takes several hours. The downsides to the test are its cost (US$50-US$100/test) and the need for a highly trained lab technician to administer the test and run sophisticated assays in a laboratory to generate results. This results in longer turnaround times (at least a day or two and up to 7-10 days during flare-ups).
Although serology tests were launched with much fanfare, demand has been limited so far. A serology test detects antibodies from a previous infection, making the individual theoretically immune. The test is simpler to administer than a molecular test because it uses a straightforward blood draw. However, one major drawback of the test is the difficulty in interpreting results. For instance, does the test detect the right antibody and what level of antibodies would confer immunity on an individual? Demand for serology tests should increase once these issues are resolved and vaccines become more widely available.
Like molecular tests, antigen tests look for a current infection. They are modestly less accurate than molecular tests but are cheaper (US$5-US$20/test), faster, simpler (no labs needed) and more scalable (can be manufactured in mass quantities). Antigen tests use a simple swab in a self-contained kit. Using Abbott’s test as an example, normal nasal secretions are swabbed, a few drops of a reactant are added and results are made available in about 15 minutes. Currently, a prescription is required, and the test needs to be administered by a health care professional (similar to a seasonal flu shot). For a summary of the key facts regarding these tests, please refer to Figure 1.
Antigen Testing a Potential Game Changer
Antigen testing could turn out to be a potential game changer that could help re-open economies worldwide. To the extent that the current testing accuracy is enough to survey broad populations with low COVID-19 prevalence, antigen testing could be used to ensure a safe environment in schools, workplaces, sporting events and cruise ships, among other public spaces. The test could also potentially more than double the number of people that can be tested globally.
Studies on antigen tests have been underway at Yale University, the University of Illinois, the State University of New York and most recently at the University Notre Dame, among others. As a result, more data should become available in the upcoming months. The availability of antigen testing has given decisionmakers at the Big Ten and Pac-12 Conferences the confidence to proceed with the college football season in the United States.
Currently, there are only half a dozen manufacturers of antigen tests and the potential revenue pie is expected to be large. Publicly traded companies include Roche; Abbott Laboratories; Becton, Dickinson and Company; and Quidel Corporation. Further, Germany-based Qiagen hopes to launch a test in the fourth quarter. We estimate that antigen tests could result in about 17% sales growth for Becton, 9% for Abbott and 7% for Roche. For the smaller Quidel, the tests could potentially double its sales.
Key assumptions behind these estimates include companies operating at a 100% capacity for a full year at the current prices. It should be noted that Roche plans to expand its current capacity from 40 million tests per month to 80 million by the year-end; Abbott from 25 million per month to 50 million in the fourth quarter; and Becton from 3 million currently to 8 million in the fourth quarter and further to 12 million per month in the first quarter of 2021.
The revenue boost should likely last until a vaccine or an even better test is made available. Antigen tests may also cannibalize molecular tests and labs. This would impact companies such as Thermo Fisher, Danaher, Quest Diagnostics, LabCorp, Biomerieux, DiaSorin, Hologic, Eurofins and Sonic Healthcare (note that Roche, Abbott, Becton and Qiagen make molecular tests, too). Given the testing needs during the pandemic, we believe these tests may prove to be complementary to each other. Diagnostic protocols may also develop such that a positive antigen test could lead to a confirmatory molecular test.
We are watching the success rate of antigen testing in a non-clinical environment. Ideally, these tests will do what they are designed to do – rapidly identify people with an active COVID-19 infection so that they may be quarantined. This could prove to be of great help for schools, offices, the travel industry and other segments of the economy.
Attainment of a fast, reliable testing would be a meaningful step toward battling COVID-19. Moreover, antigen testing could be a source of revenue growth for a limited number of companies. The availability of an antigen test product in itself may not trigger a buy or a sell rating under our process, but it may have an effect on our target prices. We would be happy to further discuss these nuances with our clients.
From an investment perspective, the Fundamental Growth and Core Equity team has been using screening tools that monitor about 400 health care companies globally for more than a decade in combination with fundamental research on those companies. We will continue to work on identifying the companies whose share prices are at odds with their long-term earnings potential.
The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without State Street Global Advisors’ express written consent.
The views expressed in this material are the views of the Fundamental Growth and Core Equity team through 09 October 2020 and are subject to change based on market and other conditions. This document contains certain statements that may be deemed forward looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected.
The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor's particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor. All information is from State Street Global Advisors unless otherwise noted and has been obtained from sources believed to be reliable, but its accuracy is not guaranteed. There is no representation or warranty as to the current accuracy, reliability or completeness of, nor liability for, decisions based on such information and it should not be relied on as such.
Past performance is not a guarantee of future results. Investing involves risk including the risk of loss of principal.
The trademarks and service marks referenced herein are the property of their respective owners. Third party data providers make no warranties or representations of any kind relating to the accuracy, completeness or timeliness of the data and have no liability for damages of any kind relating to the use of such data.
For EMEA Distribution: The information contained in this communication is not a research recommendation or ‘investment research’ and is classified as a ‘Marketing Communication’ in accordance with the Markets in Financial Instruments Directive (2014/65/EU) or applicable Swiss regulation. This means that this marketing communication (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Equity securities may fluctuate in value in response to the activities of individual companies and general market and economic conditions.
The above targets are estimates based on certain assumptions and analysis made by SSGA. There is no guarantee that the estimates will be achieved.
The stocks mentioned are not necessarily holdings invested in by SSGA or a third-party fund manager. References to specific company stocks should not be construed as recommendations or investment advice. The statements and opinions are subject to change at any time, based on market and other conditions.
SPDR ETF is the exchange traded funds ("ETF") platform of State Street Global Advisors and is comprised of funds that have been authorised by European regulatory authorities as open-ended UCITS investment companies.
SSGA SPDR ETFs Europe I and II plc issue SPDR ETFs, and is an open-ended investment company. The Company is organised as an Undertaking for Collective Investments in Transferable Securities (UCITS) under the laws of Ireland and authorised as a UCITS by the Central Bank of Ireland.
ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.
SSGA SPDR ETFS MAY NOT BE AVAILABLE OR SUITABLE FOR YOU. THE VIEWS EXPRESSED/INFORMATION IN THIS SITE DOES NOT CONSTITUTE INVESTMENT ADVICE, FINANCIAL, LEGAL, REGULATORY, ACCOUNTING OR TAX ADVICE. INDEPENDENT ADVICE SHOULD BE SOUGHT IN CASES OF DOUBT. NEITHER THE INFORMATION NOR ANY OPINION CONTAINED ON THIS SITE CONSTITUTES A SOLICITATION OR OFFER TO BUY OR SELL SHARES OF THE FUNDS OR ANY OTHER FINANCIAL INSTRUMENT.
Standard & Poor's®, S&P® and SPDR® are registered trademarks of Standard & Poor's Financial Services LLC (S&P); Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC (Dow Jones); and these trademarks have been licensed for use by S&P Dow Jones Indices LLC (SPDJI) and sublicensed for certain purposes by State Street Corporation. State Street Corporation's financial products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and third party licensors and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability in relation thereto, including for any errors, omissions, or interruptions of any index.
SPDR ETFs may be offered and sold only in those jurisdictions where authorised, in compliance with applicable regulations.
Information related to Mexico
This information does not constitute and is not intended to constitute marketing or an offer of securities and accordingly should not be construed as such. The Funds referenced herein have not been, and will not be, registered under the Mexican Securities Market Law (Ley del Mercado de Valores) and may not be publicly offered or sold in the United Mexican States. Disclosure documentation related to any of the aforementioned Funds may not be distributed publicly in Mexico and shares of the Funds may not be traded in Mexico.
You should obtain and read a prospectus and KIID relating to the SPDR ETFs prior to investing. The prospectus/KIID describing the characteristics, costs, risks and other relevant information of SPDR ETFs are available for residents of countries where SPDR ETFs are authorised for sale on the SPDRs website or from Cecabank, S.A. Alcalá 27, 28014 Madrid (Spain) who is the Spanish Representative, Paying Agent and distributor in Spain.